161 related articles for article (PubMed ID: 37373701)
1. Under the Hood: Understanding the Features of Mucin in Pseudomyxoma Peritonei.
Villarejo-Campos P; García-Arranz M; Qian S; Jiménez de Los Galanes S; Domínguez-Prieto V; Vélez-Pinto JF; Guijo Castellano I; Jiménez-Fuertes M; Guadalajara H; García-Olmo D
J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373701
[TBL] [Abstract][Full Text] [Related]
2. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
3. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
4. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
5. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
[TBL] [Abstract][Full Text] [Related]
6. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ; Semino-Mora C; Friedline CJ; Liu H; Bodi KL; McAvoy TJ; Francis J; Nieroda C; Sardi A; Dubois A; Lazinski DW; Camilli A; Testerman TL; Merrell DS
Orphanet J Rare Dis; 2013 Jul; 8():105. PubMed ID: 23844722
[TBL] [Abstract][Full Text] [Related]
7. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
8. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
9. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
10. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
11. Macroscopic and microscopic characteristics of low grade appendiceal mucinous neoplasms (LAMN) on appendectomy specimens and correlations with pseudomyxoma peritonei development risk.
Hegg KS; Mack LA; Bouchard-Fortier A; Temple WJ; Gui X
Ann Diagn Pathol; 2020 Oct; 48():151606. PubMed ID: 32889392
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological Characteristics of Pseudomyxoma Peritonei Originated from Ovaries.
Yan F; Shi F; Li X; Yu C; Lin Y; Li Y; Jin M
Cancer Manag Res; 2020; 12():7569-7578. PubMed ID: 32904568
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
15. Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry.
Guo AT; Song X; Wei LX; Zhao P
World J Gastroenterol; 2011 Aug; 17(30):3531-7. PubMed ID: 21941421
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: a case study.
Mall AS; Lotz Z; Tyler M; Goldberg P; Rodrigues J; Kahn D; Chirwa N; Govender D
Case Rep Gastroenterol; 2011 Jan; 5(1):5-16. PubMed ID: 22347149
[TBL] [Abstract][Full Text] [Related]
17. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
[TBL] [Abstract][Full Text] [Related]
18. The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review.
Lin YL; Ma R; Li Y
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2179-2188. PubMed ID: 32700107
[TBL] [Abstract][Full Text] [Related]
19. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
20. The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy.
García-Olmo D; Olmedillas-López S; Cortés-Guiral D; Villarejo P; López Rojo I; Guadalajara H; García Gómez-Heras S; García-Arranz M
Ther Adv Med Oncol; 2020; 12():1758835920928233. PubMed ID: 32636940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]